The p21 codon 31*C- and DRD2 codon 313*T-related genotypes/alleles, but not XRCC1 codon 399, hOGG1 codon 326, and DRD1-48 polymorphisms, are correlated with the presence of leiomyoma

Fertility and Sterility

Volumn 91, Issue 3, 2009, Pages 869-877

  Hsieh, Yao Yuan ^a   Chang, Chi Chen ^a   Bau, Da Tian ^a,b   Tsai, Fuu Jen ^a,b   Tsai, Chang Hai ^a,c   Chen, Chih Ping ^d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

DRD; hOGG1; leiomyoma; p21; polymorphism; XRCC1

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLYCOSYLTRANSFERASE; HUMAN 8 OXOGUANINE GLYCOSYLASE 1; PROTEIN P21; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LEIOMYOMA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION MAPPING;

CASE-CONTROL STUDIES; CODON; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA GLYCOSYLASES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEIOMYOMA; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; UTERINE NEOPLASMS;

EID: 61349174567     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.07.1328     Document Type: Article

References (94)

1. Cramer D.W. Epidemiology of myomas. Semin Reprod Endocrinol 10 (1992) 320-324
2. Townsend D.E., Sparkes R.S., Baluda M.C., and McClelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis by glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 107 (1970) 1168-1173
3. Rein M.S. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 108 Suppl 5 (2000) 791-793
4. Harris C.C., and Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329 (1993) 1318-1327
5. Li Y.J., Laurent-Puig P., Salmon R.J., Thomas G., and Hamelin R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 10 (1995) 599-601
6. el-Deiry W.S., Tokino T., Waldman T., Oliner J.D., Velculescu V.E., Burrell M., et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55 (1995) 2910-2919
7. Li X., Jiao S., and Mi R. Clinical significance of p21H-ras expression and H-ras codon 12 mutation in squamous intraepithelial lesion (SIL) and carcinoma of uterine cervix. Chung Hua Chung Liu Tsa Chih 19 (1997) 306-308
8. Levesque M.A., Katsaros D., Massobrio M., Genta F., Yu H., Richiardi G., et al. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Clin Cancer Res 6 (2000) 3260-3270
9. Jahnson S., and Karlsson M.G. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 89 (2000) 619-629
10. Cheng L., Lloyd R.V., Weaver A.L., Pisansky T.M., Cheville J.C., Ramnani D.M., et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 6 (2000) 1896-1899
11. Hsu S.L., Chen M.C., Chou Y.H., Hwang G.Y., and Yin S.C. Induction of p21(CIP1/Waf1) and activation of p34(cdc2) involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res 248 (1999) 87-96
12. Pasz-Walczak G., and Kordek R. Comparative evaluation of the expression of cell cycle regulating proteins: cyclin D1, P53 and P21 (WAF1) in colorectal cancer. Pol J Pathol 51 (2000) 63-69
13. Schneider J., Presek P., Braun A., Loffler S., and Woitowitz H.J. Serum ras (p21) as a marker for occupationally derived lung cancer?. Clin Chem Lab Med 38 (2000) 301-305
14. Koopmann J., Maintz D., Schild S., Schramm J., Louis D.N., Wiestler O.D., et al. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumors. Br J Cancer 72 (1995) 1230-1233
15. Harada K., and Ogden G.R. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol 36 (2000) 3-7
16. Lin C.S., Kuo H.H., Chen J.Y., Yang C.S., and Wang W.B. Epstein-Barr virus nuclear antigen 2 retards cell growth, induces p21(WAF1) expression, and modulates p53 activity post-translationally. J Mol Biol 303 (2000) 7-23
17. Woodward T.A., Klingler P.D., Genko P.V., and Wolfe J.T. Barrett's esophagus, apoptosis and cell cycle regulation: correlation of p53 with Bax, Bcl-2 and p21 protein expression. Anticancer Res 20 (2000) 2427-2432
18. Chen X., Danes C., Lowe M., Herliczek T.W., and Keyomarsi K. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J Natl Cancer Inst 92 (2000) 1403-1413
19. Kanavaros P., Stefanaki K., Vlachonikolis J., Eliopoulos G., Kakolyris S., Rontogianni D., et al. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas. Histol Histopathol 15 (2000) 445-453
20. Eisen J.A., and Hanawalt P.C. A phylogenomic study of DNA repair genes, proteins, and processes. Mutat Res 435 (1999) 171-213
21. Lamerdin J.E., Montgomery M.A., Stilwagen S.A., Scheidecker L.K., Tebbs R.S., Brookman K.W., et al. Genomic sequence comparison of the human and mouse XRCC1 DNA repair gene regions. Genomics 25 (1995) 547-554
22. Bu D., Tomlinson G., Lewis C.M., Zhang C., Kildebeck E., and Euhus D.M. An intronic polymorphism associated with increased XRCC1 expression, reduced apoptosis and familial breast cancer. Breast Cancer Res Treat 99 (2006) 257-265
23. Qu T., and Morimoto K. X-ray repair cross-complementing group 1 polymorphisms and cancer risks in Asian populations: a mini review. Cancer Detect Prev 29 (2005) 215-220
24. Zhao X.H., Jia G., Liu Y.Q., Liu S.W., Yan L., Jin Y., et al. Association between polymorphisms of DNA repair gene XRCC1 and DNA damage in asbestos-exposed workers. Biomed Environ Sci 19 (2006) 232-238
25. van der Straaten T., Kweekel D., Tiller M., Bogaartz J., and Guchelaar H.J. Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1. J Mol Diagn 8 (2006) 444-448
26. Monteiro E., Varzim G., Silva R., da Costa B., and Lopes C. Polymorphisms of the human OGG1 gene in laryngeal cancer: implications in radiotherapy response and survival. Rev Laryngol Otol Rhinol (Bord) 126 (2005) 135-140
27. Karahalil B., and Kocabas N.A. hOGG1 SER326CYS genetic polymorphism in a Turkish population. Arch Toxicol 79 (2005) 377-380
28. Li L., Miyamoto M., Ebihara Y., Mega S., Takahashi R., Hase R., et al. DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma. World J Surg 30 (2006) 1672-1679
29. Hayes G., Biden T.J., Selbie L.A., and Shine J. Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. Mol Endocrinol 6 (1992) 920-926
30. Tagliaferri P., Katsaros D., Clair T., Ally S., Tortora G., Neckers L., et al. Synergistic inhibition of growth of breast and colon human cancer cell lines by site selective cAMP analogues. Cancer Res 48 (1988) 1642-1650
31. Lai K.C., Chen W.C., Jeng L.B., Li S.Y., Chou M.C., and Tsai F.J. Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. Eur J Surg Oncol 31 (2005) 1135-1140
32. Chou I.C., Tsai C.H., Lee C.C., Kuo H.T., Hsu Y.A., Li C.I., et al. Association analysis between Tourette's syndrome and dopamine D1 receptor gene in Taiwanese children. Psychiatr Genet 14 (2004) 219-221
33. Lee C.C., Chou I.C., Tsai C.H., Wang T.R., Li T.C., and Tsai F.J. Dopamine receptor D2 gene polymorphisms are associated in Taiwanese children with Tourette syndrome. Pediatr Neurol 33 (2005) 272-276
34. Hsieh Y.Y., Chang C.C., Tsai F.J., Hsu C.M., Lin C.C., and Tsai C.H. The C-related genotype and allele for E-cadherin 3'-UTR Pml I polymorphism are associated with higher susceptibility to endometriosis. Genet Mol Biol 28 (2005) 661-664
35. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
36. Gujuluva C.N., Baek J.H., Shin K.H., Cherrick H.M., and Park N.H. Effect of UV-irradiation on cell cycle, viability and the expression of p53, gadd153 and gadd45 genes in normal and HPV-immortalized human oral keratinocytes. Oncogene 9 (1994) 1819-1827
37. Cao L., Yang Z., and Li X. Expression and significance of tumor suppressor gene WAF1 in epithelial ovarian neoplasms. Hunan I Ko Ta Hsueh Hsueh Pao 23 (1998) 602-604
38. Huang S.P., Wu W.J., Chang W.S., Wu M.T., Chen Y.Y., Chen Y.J., et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 2217-2224
39. Su L., Liu G., Zhou W., Xu L.L., Miller D.P., Park S., et al. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 12 (2003) 174-175
40. Roh J.W., Kim J.W., Park N.H., Song Y.S., Park I.A., Park S.Y., et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 93 (2004) 499-505
41. Tsai F.J., Lin H.J., Chen W.C., Tsai C.H., and Tsai S.W. A codon 31ser-arg polymorphism of the AF-1/CIP-1/p21/tumour suppressor gene in Chinese primary open-angle glaucoma. Acta Ophthalmol Scand 82 (2004) 76-80
42. Chen W.C., Wu H.C., Hsu C.D., Chen H.Y., and Tsai F.J. p21 gene codon 31 polymorphism is associated with bladder cancer. Urol Oncol 7 (2002) 63-66
43. Chen W.C., Lu H.F., Chen H.Y., Hsu C.D., and Tsai F.J. Arginine form of p21 gene codon 31 is less prominent in patients with calcium oxalate stone. Urol Res 29 (2001) 94-97
44. Tsai M.H., Chen W.C., and Tsai F.J. Correlation of p21 gene codon 31 polymorphism and TNF-alpha gene polymorphism with nasopharyngeal carcinoma. J Clin Lab Anal 16 (2002) 146-150
45. Hsieh Y.Y., Tsai F.J., Chang C.C., Chen W.C., Tsai C.H., Tsai H.D., et al. p21 gene codon 31 arginine/serine polymorphism: non-association with endometriosis. J Clin Lab Anal 15 (2001) 184-187
46. Jiao L., Bondy M.L., Hassan M.M., Wolff R.A., Evans D.B., Abbruzzese J.L., et al. Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev 30 (2006) 284-291
47. Cao Y., Miao X.P., Huang M.Y., Deng L., Hu L.F., Ernberg I., et al. Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer 6 (2006) 167
48. Park J., Chen L., Tockman M.S., Elahi A., and Lazarus P. The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. Pharmacogenetics 14 (2004) 103-109
49. Kim E.J., Jeong P., Quan C., Kim J., Bae S.C., Yoon S.J., et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65 (2005) 70-75
50. Tsukino H., Hanaoka T., Otani T., Iwasaki M., Kobayashi M., Hara M., et al. hOGG1 Ser326Cys polymorphism, interaction with environmental exposures, and gastric cancer risk in Japanese populations. Cancer Sci 95 (2004) 977-983
51. Lee Y.L., Chen W., Tsai W.K., Lee J.C., Chiou H.L., Shih C.M., et al. Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. J Lab Clin Med 147 (2006) 228-233
52. Tsai Y.Y., Cheng Y.W., Lee H., Tsai F.J., Tseng S.H., Lin C.L., et al. Oxidative DNA damage in pterygium. Mol Vis 11 (2005) 71-75
53. Basu S., and Dasgupta P.S. Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig Dis Sci 44 (1999) 916-921
54. Beige J., Bellmann A., Sharma A.M., and Gessner R. Ethnic origin determines the impact of genetic variants in dopamine receptor gene (DRD1) concerning essential hypertension. Am J Hypertens 17 (2004) 1184-1187
55. Hansen K.A., Zhang Y., Colver R., Tho S.P., Plouffe Jr. L., and McDonough P.G. The dopamine receptor D2 genotype is associated with hyperprolactinemia. Fertil Steril 84 (2005) 711-718
56. Kukreti R., Tripathi S., Bhatnagar P., Gupta S., Chauhan C., Kubendran S., et al. Association of DRD2 gene variant with schizophrenia. Neurosci Lett 392 (2006) 68-71
57. Lu Y., Zhu H., Wang X., Snieder H., Huang Y., Harshfield G.A., et al. Effects of dopamine receptor type 1 and Gs protein alpha subunit gene polymorphisms on blood pressure at rest and in response to stress. Am J Hypertens 19 (2006) 832-836
58. Shintani S., Matsuo K., Crohin C.C., McBride J., Tsuji T., Donoff R.B., et al. Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes. Cancer Res 59 (1999) 4142-4147
59. Kennon B., Ingram M.C., Friel E.C., Anderson N.H., MacKenzie S.M., Davies E., et al. Aldosterone synthase gene variation and adrenocortical response to sodium status, angiotensin II and ACTH in normal male subjects. Clin Endocrinol (Oxf) 61 (2004) 174-181
60. Shirasawa S., Harada H., Furugaki K., Akamizu T., Ishikawa N., Ito K., et al. SNPs in the promoter of a B cell specific antisense transcript, SAS-ZFAT, determine susceptibility to autoimmune thyroid disease. Hum Mol Genet 13 (2004) 2221-2231
61. *C-related genotypes and alleles are associated with higher susceptibilities of endometriosis and leiomyoma. Mol Hum Reprod 13 (2007) 117-122
62. Lee J.E., Lee S.J., Namkoong S.E., Um S.J., Sull J.W., Jee S.H., et al. Gene-gene and gene-environmental interactions of p53, p21, and IRF-1 polymorphisms in Korean women with cervix cancer. Int J Gynecol Cancer 14 (2004) 118-125
63. Roh J., Kim M., Kim J., Park N., Song Y., Kang S., et al. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett 165 (2001) 59-62
64. Powell B.L., van Staveren I.L., Roosken P., Grieu F., Berns E.M., and Iacopetta B. Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 23 (2002) 311-315
65. Bhattacharya P., and Sengupta S. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women. Gynecol Oncol 99 (2005) 176-182
66. Li G., Liu Z., Sturgis E.M., Shi Q., Chamberlain R.M., Spitz M.R., et al. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 26 (2005) 1596-1602
67. Xi Y.G., Ding K.Y., Su X.L., Chen D.F., You W.C., Shen Y., et al. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 25 (2004) 2201-2206
68. Wu M.T., Wu D.C., Hsu H.K., Kao E.L., Yang C.H., and Lee J.M. Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population. Cancer Lett 201 (2003) 175-180
69. Ressiniotis T., Griffiths P.G., Keers S.M., Chinnery P.F., and Birch M. A polymorphism at codon 31 of gene p21 is not associated with primary open angle glaucoma in Caucasians. BMC Ophthalmol 5 (2005) 5
70. Wu M.T., Chen M.C., and Wu D.C. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett 205 (2004) 61-68
71. Duarte M.C., Colombo J., Rossit A.R., Caetano A., Borim A.A., Wornrath D., et al. Polymorphisms of DNA repair genes XRCC1 and XRCC3, interaction with environmental exposure and risk of chronic gastritis and gastric cancer. World J Gastroenterol 11 (2005) 6593-6600
72. Shen J., Gammon M.D., Terry M.B., Wang L., Wang Q., Zhang F., et al. Polymorphisms in XRCC1 modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, dietary antioxidants, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14 (2005) 336-342
73. Goodman M., Bostick R.M., Ward K.C., Terry P.D., van Gils C.H., Taylor J.A., et al. Lycopene intake and prostate cancer risk: effect modification by plasma antioxidants and the XRCC1 genotype. Nutr Cancer 55 (2006) 13-20
74. Chen L., Ambrosone C.B., Lee J., Sellers T.A., Pow-Sang J., and Park J.Y. Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol 175 (2006) 108-112
75. Majumder M., Sikdar N., Paul R.R., and Roy B. Increased risk of oral leukoplakia and cancer among mixed tobacco users carrying XRCC1 variant haplotypes and cancer among smokers carrying two risk genotypes: one on each of two loci, GSTM3 and XRCC1 (codon 280). Cancer Epidemiol Biomarkers Prev 14 (2005) 2106-2112
76. Stern M.C., Siegmund K.D., Corral R., and Haile R.W. XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. Cancer Epidemiol Biomarkers Prev 14 (2005) 609-615
77. Joseph T., Kusumakumary P., Chacko P., Abraham A., and Pillai M.R. DNA repair gene XRCC1 polymorphisms in childhood acute lymphoblastic leukemia. Cancer Lett 217 (2005) 17-24
78. Ratnasinghe L.D., Abnet C., Qiao Y.L., Modali R., Stolzenberg-Solomon R., Dong Z.W., et al. Polymorphisms of XRCC1 and risk of esophageal and gastric cardia cancer. Cancer Lett 216 (2004) 157-164
79. Yu H.P., Zhang X.Y., Wang X.L., Shi L.Y., Li Y.Y., Li F., et al. DNA repair gene XRCC1 polymorphisms, smoking, and esophageal cancer risk. Cancer Detect Prev 28 (2004) 194-199
80. Duell E.J., Holly E.A., Bracci P.M., Wiencke J.K., and Kelsey K.T. A population-based study of the Arg399Gln polymorphism in X-ray repair cross complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res 62 (2002) 4630-4636
81. Yu M.W., Yang S.Y., Pan I.J., Lin C.L., Liu C.J., Liaw Y.F., et al. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 95 (2003) 1485-1488
82. Mertens A.C., Mitby P.A., Radloff G., Jones I.M., Perentesis J., Kiffmeyer W.R., et al. XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer 101 (2004) 1463-1472
83. Varzim G., Monteiro E., Silva R.A., Fernandes J., and Lopes C. CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx. Eur J Cancer Prev 12 (2003) 495-499
84. Kau H.C., Tsai C.C., Hsu W.M., Liu J.H., and Wei Y.H. Genetic polymorphism of hOGG1 and risk of pterygium in Chinese. Eye 18 (2004) 635-639
85. Cho E.Y., Hildesheim A., Chen C.J., Hsu M.M., Chen I.H., Mittl B.F., et al. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiol Biomarkers Prev 12 (2003) 1100-1104
86. Poplawski T., Arabski M., Kozirowska D., Blasinska-Morawiec M., Morawiec Z., Morawiec-Bajda A., et al. DNA damage and repair in gastric cancer-A correlation with the hOGG1 and RAD51 genes polymorphisms. Mutat Res 601 (2006) 83-91
87. Hu Y.C., and Ahrendt S.A. hOGG1 Ser326Cys polymorphism and G:C-to-T:A mutations: no evidence for a role in tobacco-related non small cell lung cancer. Int J Cancer 114 (2005) 387-393
88. Park Y.J., Choi E.Y., Choi J.Y., Park J.G., You H.J., and Chung M.H. Genetic changes of hOGG1 and the activity of oh8Gua glycosylase in colon cancer. Eur J Cancer 37 (2001) 340-346
89. Liang G., Pu Y., and Yin L. Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population. Cancer Lett 223 (2005) 265-274
90. Wang C.L., Hsieh M.C., Hsin S.C., Lin H.Y., Lin K.D., Lo C.S., et al. The hOGG1 Ser326Cys gene polymorphism is associated with decreased insulin sensitivity in subjects with normal glucose tolerance. J Hum Genet 51 (2006) 124-128
91. Dmitrzak-Weglarz M., Rybakowski J.K., Slopien A., Czerski P.M., Leszczynska-Rodziewicz A., Kapelski P., et al. Dopamine receptor D1 gene-48A/G polymorphism is associated with bipolar illness but not with schizophrenia in a Polish population. Neuropsychobiology 53 (2006) 46-50
92. Misener V.L., Luca P., Azeke O., Crosbie J., Waldman I., Tannock R., et al. Linkage of the dopamine receptor D1 gene to attention-deficit/hyperactivity disorder. Mol Psychiatry 9 (2004) 500-509
93. Kojima H., Ohmori O., Shinkai T., Terao T., Suzuki T., and Abe K. Dopamine D1 receptor gene polymorphism and schizophrenia in Japan. Am J Med Genet 88 (1999) 116-119
94. Gelernter J., Pauls D.L., Leckman J., Kidd K.K., and Kurlan R. D2 dopamine receptor alleles do not influence severity of Tourette's syndrome. Results from four large kindreds. Arch Neurol 51 (1994) 397-400